Global pharma companies and Japan can create a win-win situation through a new pricing mechanism, writes Nobuko Kobayashi.
Innovations in Big Data will have a lasting impact on care and present an opportunity for U.S. pharmaceutical companies, writes Nobuko Kobayashi.